Clinical Trials Browser

Colonic Neoplasms, Pancreatic Neoplasms, Disease Progression

NCT04886531 2026-04-08

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06109467 2026-02-09

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Phase 2 Recruiting

36 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05933395 2026-01-20

GERTRUDE

Phase 2 Recruiting

135 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04965064 2025-12-15

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Phase 2 Recruiting

22 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT02977780 2025-11-10

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Phase 2 Recruiting

460 enrolled

CNS

Glioblastoma

NCT06008275 2025-11-10

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Phase EARLY_PHASE1 Recruiting

20 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05274048 2025-10-29

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Phase 1 Recruiting

18 enrolled

Gastrointestinal

Gastrointestinal Neoplasms, Stomach Neoplasms

NCT05760612 2025-09-25

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Phase 3 Recruiting

300 enrolled

Breast

Breast Neoplasms

NCT05919108 2025-09-09

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Phase 2 Recruiting

30 enrolled

Carcinoma, Lobular

NCT05615818 2025-04-23

SAFIR-ABC10

Phase 3 Recruiting

800 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT05388149 2025-01-31

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

Phase 2 Recruiting

15 enrolled

Breast

Breast Neoplasms

NCT06693024 2024-11-20

NeraHER2

Recruiting

2,806 enrolled

Breast

HER2-positive Breast Cancer

Clinical Trials

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

I-SPY

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

GERTRUDE

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

SAFIR-ABC10

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

NeraHER2